Dennis Thompson, HealthDay News An experimental DNA-based vaccine protected monkeys from infection with the Zika virus, and it has proceeded to human safety trials, researchers report.

New York, March 26 Creative Biolabs, a leading pre-clinical vaccine development and production company, now offers safe and efficacious nucleic acid vaccines, that is, DNA and RNA vaccine.. As a professional, Creative Biolabs has effectively supported the vaccine industry for decades with a full range of vaccine design and production services and related products. We combine the traditional and the most updated genetic engineering technologies to efficiently produce highly immunogenic vaccines addressing urgent unmet medical needs.. A vaccine is a biological agent that provides active acquired immunity to a particular disease and usually contains an agent that resembles a disease-causing microorganism. In contrast to recombinant bacteria or virus vaccines, nucleic acid vaccines consist only of DNA or RNA, which is uptake by cells and transformed into protein, protecting against disease by injection with genetically engineered DNA (as a plasmid) or RNA (as mRNA). Their immunogenicity and efficacy ...

Our previous studies have shown that therapeutic DNA vaccine induction of mucosal responses correlated with significant reduction of virus in the gut of SIV-inf...

TY - JOUR. T1 - Enhancing DNA vaccine potency by combining a strategy to prolong dendritic cell life and intracellular targeting strategies with a strategy to boost CD4+ T cell. AU - Kim, Daejin. AU - Hoory, Talia. AU - Wu, T. C.. AU - Hung, Chien Fu. PY - 2007/11/1. Y1 - 2007/11/1. N2 - Intradermal administration of DNA vaccines, using a gene gun, represents an effective means of delivering DNA directly into professional antigen-presenting cells (APCs) in the skin and thus allows the application of strategies to modify the properties of APCs to enhance DNA vaccine potency. In the current study, we hypothesized that the potency of human papillomavirus (HPV) type 16 E7 DNA vaccines employing intracellular targeting strategies combined with a strategy to prolong the life of dendritic cells (DCs) could be further enhanced by the addition of a DNA vaccine capable of generating high numbers of pan-HLA-DR reactive epitope (PADRE)-specific CD4+ T cells. We observed that the addition of PADRE DNA to E7 ...

Safety, tolerability, and immunogenicity of two Zika virus DNA vaccine candidates in healthy adults: randomised, open-label, phase 1 clinical trials

Due to their rapid and widespread development, DNA vaccines have entered into a variety of human clinical trials for vaccines against various diseases including cancer. Evidence that DNA vaccines are well tolerated and have an excellent safety profile proved to be of advantage as many clinical trials combines the first phase with the second, saving both time and money. It is clear from the results obtained in clinical trials that such DNA vaccines require much improvement in antigen expression and delivery methods to make them sufficiently effective in the clinic. Similarly, it is clear that additional strategies are required to activate effective immunity against poorly immunogenic tumor antigens. Engineering vaccine design for manipulating antigen presentation and processing pathways is one of the most important aspects that can be easily handled in the DNA vaccine technology. Several approaches have been investigated including DNA vaccine engineering, co-delivery of immunomodulatory molecules, safe

DNA vaccines have progressed rapidly from the conceptual stage to the stage of clinical trials. While studies in small laboratory animals have shown great promise, initial reports from human studies were less encouraging. Progress is being made, however, documented by the papers presented here. This volume contains the proceedings of a meeting devoted to the latest developments in DNA vaccines, from laboratory studies to clinical trials. The papers, written by leaders in the field, focus on the current state of DNA vaccines in humans and other large animals. The bulk of the studies involve DNA vaccines against HIV/SIV. Other promising trials make use of DNA vaccines against malaria and hepatitis B. The papers inform the reader about the immune basis of this form of vaccination and about approaches being developed to increase the efficacy of DNA vaccines in humans. These include the co-administration of cytokines, prime-boost strategies, optimising codon usage or the use of CpG motifs. An ...

The coronavirus family member, SARS-CoV-2 has been identified as the causal agent for the pandemic viral pneumonia disease, COVID-19. At this time, no vaccine is available to control further dissemination of the disease. We have previously engineered a synthetic DNA vaccine targeting the MERS coronavirus Spike (S) protein, the major surface antigen of coronaviruses, which is currently in clinical study. Here we build on this prior experience to generate a synthetic DNA-based vaccine candidate targeting SARS-CoV-2 S protein. The engineered construct, INO-4800, results in robust expression of the S protein in vitro. Following immunization of mice and guinea pigs with INO-4800 we measure antigen-specific T cell responses, functional antibodies which neutralize the SARS-CoV-2 infection and block Spike protein binding to the ACE2 receptor, and biodistribution of SARS-CoV-2 targeting antibodies to the lungs. This preliminary dataset identifies INO-4800 as a potential COVID-19 vaccine candidate, ...

This topic contains 2 study abstracts on Vaccination: Plasmid DNA Vaccines indicating they may negatively impact Infertility, Vaccination: Abortion, and Vaccine-induced Toxicity

CCL2 DNA vaccines are directed against the host chemoattractant molecule CCL2 (MCP-1), a key chemokine in recruiting macrophages to sites of inflammation. Macrophages recruited by CCL2 lead to progressive renal injury. In rat models of disease unmodified CCL2 DNA vaccine in combination with a CCL5 (RANTES) DNA vaccine can protect against chronic renal disease. The mechanism of protection involves the induction of auto-antibodies to the CCL2. Introduction of the adjuvant p-tet into the DNA structure of the CCL2 vaccine leads to enhanced potency with the induction of specific Th1 cellular immunity. The strategies outlined here demonstrate a model for developing potent vaccines against highly restricted self targets.

In addition to the general medical benefits, DNA vaccines can provide a large economic benefit. Due to the decreased restrictions in the production and storage of DNA vaccines compared to regular vaccines, the cost of producing and maintaining DNA vaccines is much lower. This can be especially beneficial to people in developing countries. According to certain case studies, the cost of developing and manufacturing a successful and beneficial conventional vaccine can range from $500 million to $1 billion. Comparatively, the development and manufacturing of a DNA vaccine ranges between $200 and $300 million ...

A novel DNA vaccine vector encoding the Mycobacterium tuberculosis secreted antigen Ag85A fused with the influenza A virus (IAV) HA2 protein epitopes, pEGFP/Ag85A-sHA2 (pAg85A-sHA2), was designed to provide protection against influenza. The antigen encoded by the DNA vaccine vector was efficiently expressed in mammalian cells, as determined by reverse transcription polymerase chain reaction (RT-PCR) and fluorescence analyses. Mice were immunized with the vaccine vector by intramuscular injection before challenge with A/Puerto Rico/8/34 virus (PR8 virus). Sera and the splenocyte culture IFN-γ levels were significantly higher in immunized mice compared with the control mice. The novel vaccine group showed a high neutralization antibody titer in vitro. The novel vaccine vector also reduced the viral loads, increased the survival rates in mice after the PR8 virus challenge and reduced the alveolar inflammatory cell numbers. Sera IL-4 concentrations were significantly increased in mice immunized with the

Nucleic acid vaccines, like other biotechnology derived vaccines, will be evaluated on a case-by-case basis. Evaluation of vaccine master seeds is an essential first step for fulfilling these requirements.

T. gondii is an important zoonotic Apicomplexan parasite, but no drugs could eliminate the pathogen from the host effectively. In recent studies, DNA vaccines have shown the potential to defend against T. gondii infection in view of their abilities to induce long-term humoral and cellular immune responses in animal models. Many rhoptry proteins (ROP5, ROP13, ROP16 and ROP18) [16-19] are identified to be potential candidates for development of T. gondii DNA vaccines. TgROP38, a new member of the rhoptry protein family, was firstly identified by the phylogenomic approach and was found to regulate the expression of host transcription factors, signaling pathways and cell proliferation, and apoptosis that sum up about 1200 host genes [21]. These key biological roles of TgROP38 in T. gondii infection of the host have stimulated us to evaluate whether TgROP38 could elicit effective immune responses against infection with T. gondii in the mice model. Therefore, we constructed the recombinant plasmid ...

The spleens of intramuscularly or gene gun immunized mice enlarged notably compared with those of the unimmunized controls. In particular, the spleen weight of the gene gun injected mice almost doubled that of the unimmunized controls (data not shown). FACS analysis of spleen cells harvested 2 weeks after the final immunization with AMA-1 or AMA-1 plus IL-12 DNA vaccines showed notable differences in the proportions of CD4+ and CD8+ T-lymphocytes between the intramuscular injection versus the gene gun (epidermis) injection (Fig. 2). In mice immunized intramuscularly (n=5 for each group) with AMA-1 alone or AMA-1 plus IL-12 DNA vaccines, the proportions of T-cell subsets (17.9±0.47% or 15.5±0.79% for CD8+ T-cells and 27.6±0.84% or 27.7±0.72% for CD4+ T-cells) did not show any significant changes (P,0.05), compared with control mice immunized only with UB vector (16.2±0.78% for CD8+ T-cells and 26.5±0.35% for CD4+ T-cells) (Fig. 2). By contrast, in mice injected with a gene gun (n=3 for each ...

The effectiveness of a vaccine may be increased when combined with an adjuvant and/or when given with EP. The addition of an adjuvant or EP may increase a persons immune response to a vaccine. Furthermore, the immune response to HIV antigens may be improved by giving a DNA vaccine boosted with a live vector vaccine. The purpose of this study is to evaluate the safety, tolerability, and immunogenicity of an HIV DNA vaccine (HIV-MAG) alone or in combination with an IL-12 pDNA adjuvant, delivered IM via EP followed by a Vesicular Stomatitis Virus (VSV) HIV gag vaccine boost given IM by needle and syringe in healthy, HIV-uninfected adults.. Participants will be enrolled into the study in one of four groups. Each of the four groups will receive 3 mg of the HIV-MAG vaccine alone or combined with one of three different doses of the IL-12 pDNA adjuvant, followed by the VSV HIV gag vaccine boost. Within each of the four groups, participants will be randomly assigned to receive the study vaccines or ...

The effectiveness of a vaccine may be increased when combined with an adjuvant and/or when given with EP. The addition of an adjuvant or EP may increase a persons immune response to a vaccine. Furthermore, the immune response to HIV antigens may be improved by giving a DNA vaccine boosted with a live vector vaccine. The purpose of this study is to evaluate the safety, tolerability, and immunogenicity of an HIV DNA vaccine (HIV-MAG) alone or in combination with an IL-12 pDNA adjuvant, delivered IM via EP followed by a Vesicular Stomatitis Virus (VSV) HIV gag vaccine boost given IM by needle and syringe in healthy, HIV-uninfected adults.. Participants will be enrolled into the study in one of four groups. Each of the four groups will receive 3 mg of the HIV-MAG vaccine alone or combined with one of three different doses of the IL-12 pDNA adjuvant, followed by the VSV HIV gag vaccine boost. Within each of the four groups, participants will be randomly assigned to receive the study vaccines or ...

DNA Vaccine Adjuvants pBOOST plasmids were developed as genetic adjuvants for DNA vaccines to potentiate the immune response to a specific antigen. The method of plasmid DNA vaccine delivery is known to bias the immune response to a specific antigen towa

Developing vaccines for the prevention of human infection by H5N1 influenza viruses is an urgent task. DNA vaccines are a novel alternative to conventional vaccines and should contribute to the prophylaxis of emerging H5N1 virus. In this study, we assessed whether a single immunization with plasmid DNA expressing H5N1 hemagglutinin (HA) could provide early protection against lethal challenge in a mouse model. Mice were immunized once with HA DNA at 3, 5, 7 days before a lethal challenge. The survival rate, virus titer in the lungs and change of body weight were assayed to evaluate the protective abilities of the vaccine. To test the humoral immune response induced by HA DNA, serum samples were collected through the eye canthus of mice on various days after immunization and examined for specific antibodies by ELISA and an HI assay. Splenocytes were isolated after the immunization to determine the antigen-specific T-cell response by the ELISPOT assay. Challenge experiments revealed that a single

DNA vaccination is a technique for protecting against disease by injection with genetically engineered DNA so cells directly produce an antigen, producing a protective immunological response. DNA vaccines have potential advantages over conventional vaccines, including the ability to induce a wider range of immune response types. Several DNA vaccines are available for veterinary use. Currently no DNA vaccines have been approved for human use. Research is investigating the approach for viral, bacterial and parasitic diseases in humans, as well as for several cancers. Vaccines have eliminated naturally occurring smallpox, and nearly eliminated polio, while other diseases, such as typhus, rotavirus, hepatitis A and B and others are well controlled. Conventional vaccines cover a small number of diseases, while other infections kill millions of people every year. First generation vaccines are whole-organism vaccines - either live and weakened, or killed forms. Live, attenuated vaccines, such as ...

To further improve fertility of animals, a novel gene RFRP-3 (RF-amide related peptide-3,RFRP-3) was used to construct DNA vaccines with INH α (1-32) (inhibin, IN...

DNA vaccination holds great promise for the prevention and treatment of cancer and infectious diseases. However, the clinical ability of DNA vaccines is still controversial due to the limited immune response initially observed in humans. We hypothesized that electroporation of a plasmid encoding the HIV-1 Gag viral capsid protein would enhance cancer DNA vaccine potency. DNA electroporation used to deliver plasmids in vivo, induced type I interferons, thereby supporting the activation of innate immunity. The coadministration of ovalbumin (OVA) and HIV-1 Gag encoding plasmids modulated the adaptive immune response. This strategy favored antigen-specific Th1 immunity, delayed B16F10-OVA tumor growth and improved mouse survival in both prophylactic and therapeutic vaccination approaches. Similarly, a prophylactic DNA immunization against the melanoma-associated antigen gp100 was enhanced by the codelivery of the HIV-1 Gag plasmid. The adjuvant effect was not driven by the formation of HIV-1 Gag ...

Scientists have developed a novel method for delivering therapeutic molecules into cells. The method harnesses gold nanoparticles that are electrically activated, causing them to oscillate and bore holes in cells outer membranes and allowing key molecules - such as DNA, RNA, and proteins - to gain entry.

Abstract Autophagy plays an important role in neoplastic transformation of cells and in resistance of cancer cells to radio and chemotherapy. p62 (SQSTM1) is a key component of autophagic machinery which is also involved in signal transduction. Although recent empirical observations demonstrated that p62 is overexpressed in variety of human tumors, a mechanism of p62 overexpression is not known. Here we report that the transformation of normal human mammary epithelial cells with diverse oncogenes (RAS, PIK3CA and Her2) causes marked accumulation of p62. Based on this result, we hypothesized that p62 may be a feasible candidate to be an anti- cancer DNA vaccine. Here we performed a preclinical study of a novel DNA vaccine encoding p62. Intramuscularly administered p62-encoding plasmid induced anti-p62 antibodies and exhibited strong antitumor activity in three models of allogeneic mouse tumors - B16 melanoma, Lewis lung carcinoma (LLC), and S37 sarcoma. P62-encoding plasmid has demonstrated its ...

In this work, we report the evaluation of two DNA vaccines against dengue-3 virus (DENV-3). The first construction, called pVAC3DEN3, was engineered inserting the pre-membrane (prM) and envelope (E) gene of DENV-3 truncated with a restriction site between them, as previously described. The second construction was developed cloning the full gene sequence of prM and E from DENV-3 virus in pCI plasmid for mammalian expression and was denominated pVAC1WDEN3. The results showed that both constructions were capable of expressing the prM and E proteins, as demonstrated by ELISA and immunoblotting detection in cell culture transfected with the plasmids. After positive

PowderMed Ltd. (a subsidiary of Pfizer) was developing a therapeutic DNA vaccine for the treatment of genital warts caused by the human papillomavirus (HPV).

With increasing prophylactic HPV vaccination rates among the general population and the expansion of FDA approval for vaccination of all age groups, the rates of HPV infection and subsequent malignancy are set to drop over the coming decades.3 27 There remains, however, an unmet need for an HPV therapeutic vaccine. Currently, there are over 10 HPV therapeutic vaccines under development, and in various stages of clinical testing, but mostly in phase I or II.11 Vaccines are being developed employing multiple platforms, including DNA, bacterial and viral vectors, peptides and proteins. VGX-3100 is an HPV 16/18 DNA-based vaccine that is administered intramuscularly via electroporation, and is currently being tested in a phase III trial (NCT03721978) for high-grade cervical lesions, CIN2/3, which are a direct precursor to cervical cancer. AXAL-CERV is a Listeria monocytogenes-based vaccine currently in a phase III clinical trial to treat patients with high risk locally advanced cervical cancer (NCT ...

Influenza is one of the most important illnesses in the modern world, causing great public health losses each year due to the lack of medication and broadly protective, long-lasting vaccines. The development of highly immunogenic and safe vaccines is currently one of the major problems encountered in efficient influenza prevention. DNA vaccines represent a novel and powerful alternative to the conventional vaccine approaches. To improve the efficacy of the DNA vaccine against influenza H5N1, we inserted three repeated kappa B (κB) motifs, separated by a 5-bp nucleotide spacer, upstream of the cytomegalovirus promoter and downstream of the SV40 late polyadenylation signal. The κB motif is a specific DNA element (10pb-long) recognized by one of the most important transcription factors NFκB. NFκB is present in almost all animal cell types and upon cell stimulation under a variety of pathogenic conditions. NFκB is released from IκB and translocates to the nucleus and binds to κB sites, ...

DNA vaccines promote an immune response by providing antigen-encoding DNA to the recipient, but the efficacy of such vaccines needs improving. Many approaches have considerable potential but currently induce relatively weak immune responses despite multiple high doses of DNA vaccine. Here, we asked whether targeting vaccine antigens to DCs would increase the immunity and protection that result from DNA vaccines. To determine this, we generated a DNA vaccine encoding a fusion protein comprised of the vaccine antigen and a single-chain Fv antibody (scFv) specific for the DC-restricted antigen-uptake receptor DEC205. Following vaccination of mice, the vaccine antigen was expressed selectively by DCs, which were required for the increased efficacy of MHC class I and MHC class II antigen presentation relative to a control scFv DNA vaccine. In addition, a DNA vaccine encoding an HIV gag p41-scFv DEC205 fusion protein induced 10-fold higher antibody levels and increased numbers of IFN-γ-producing CD4+ ...

Researchers at the Johns Hopkins Bloomberg School of Public Health and Emory developed a DNA vaccine proven to protect against measles, the most conclusive evidence yet that DNA vaccines may be useful in the fight against human disease.

A novel synthetic DNA vaccine can, for the first time, induce protective immunity against the Middle East Respiratory Syndrome (MERS) coronavirus in animal species, reported researchers from the Perelman School of Medicine at the University of Pennsylvania.

Speaker: Honorary Doctor of Karolinska Institutet Margaret A. Liu Host: Francesca Chiodi Dr Margaret A. Liu has been appointed Honorary Doctor of Karolinska Institutet; she is honored for her frontline research and education within the field of DNA-based vaccines. Margaret Liu is the President of the International Society of Vaccines, the founder of ProTherImmune and she is affiliated with University of California, San Francisco, and Karolinska Institutet

Straus compared dl5-29 with a glycoprotein vaccine previously tested in humans and a third vaccine comprising a naked circular strand of DNA encoding the glycoprotein. Naked DNA vaccines have generated interest in recent years for their potential to elicit a stronger cellular immune response than by simply injecting the protein. Straus said that he tested dl5-29 against the best tested standard vaccine plus the competing new concept in the field, DNA vaccines, in order to get a better sense of how well the dl 5-29 vaccine performed. His team tested the vaccines both in mice and in guinea pigs. The latter is the best model of human HSV-2 disease because it is the only one that mimics many of the aspects of the human disease, such as a recurring infection interspersed with periods of latency. The researchers studied how well the vaccines worked prophylactically-to prevent infection-and therapeutically to help control an existing infection ...

The COVID-19 pandemic is accelerating development and clinical evaluation of plasmid DNA vaccines and other nucleic-acid-based therapies.

Health,Swedish researchers have expressed hope regarding the DNA vaccine tria...DNA vaccines represent the latest innovation in the area of vaccin...The technology is highly promising for producing simple inexpens...Although the study is not yet over the researchers are very posit...The second phase trial targeted at testing the effectiveness of t...,DNA,Vaccine,Trials,Against,HIV,Virus,In,Sweden,Nurture,Hope,medicine,medical news today,latest medical news,medical newsletters,current medical news,latest medicine news

Vical Incorporated (Nasdaq VICL) announced today that the company s Vaxfectin adjuvant has significantly boosted the immune response of DNA-based vaccines again

Researchers have made significant progress in the development of a potential vaccine to protect against HIV infection. For the first time, researchers have shown that a combined approach - using a common cold virus to introduce a vaccine into the body, as well as an injection of a DNA-based vaccine - results in the immune system actively protecting against HIV in the gut and bodily cavities.

Our data demonstrate that a single dose of a DNA vaccine or a purified inactivated virus vaccine provides complete protection against the ZIKV challenge in mice, said senior author Dan H. Barouch, MD, PhD, Director of the Center for Virology and Vaccine Research at BIDMC, Professor of Medicine at Harvard Medical School, and Steering Committee member at the Ragon Institute of MGH, MIT and Harvard. Importantly, we showed that vaccine-induced antibodies provided protection, similar to existing vaccines for other flaviviruses. The researchers tested two vaccine candidates: a DNA vaccine developed in the Barouch laboratory at BIDMC, and a purified inactivated virus vaccine developed at WRAIR. The DNA vaccine used gene sequences from a ZIKV strain from Brazil to elicit immune responses. Four weeks following vaccination, mice were exposed to the Brazilian strain of ZIKV, which had previously been shown to cause defects in fetal mice similar to those observed in ZIKV infected humans. All vaccinated ...

A research paper has been published on the three potential Zika virus vaccines that are being tested in humans at present. Two are based on cutting-edge DNA vaccine technology and the third is based on the more standard inactivated virus model.. The DNA vaccines under development interfere with the virus ability to enter cells and replicate itself, while the inactivated vaccine aims to create an immune response that would provide future protection against Zika.. Of the three, a DNA vaccine developed by the US National Institutes of Health has progressed the furthest, with a large multi-site phase 2 trial underway involving almost 2500 test subject.. Stephen Thomas, one of the authors of the paper, said research and development has been incredibly brisk and that some groundbreaking strides have been made in very short periods of time.. The paper states: The development of a safe and effective vaccine is an urgent global health priority. Promising data from preclinical vaccine studies in ...

STONY BROOK, N.Y., & ROME - April 2, 2020 - Applied DNA Sciences Inc. - a specialist in Polymerase Chain Reaction (PCR)-based DNA manufacturing that enables diagnostics, pre-clinical nucleic acid-based therapeutic drug candidates, supply chain security, anti-counterfeiting and anti-theft technology - and Takis Biotech, a company focused on the development of cancer vaccines and founded by scientists from Merck Research Laboratories, today announce an expansion of their COVID-19 vaccine development program to include a fifth vaccine candidate. Production of all vaccine candidates is expected to be completed this month at Applied DNAs LinearDNA™ production facility in Stony Brook, N.Y. All vaccine candidates have also been approved by Italys Ministry of Health for preclinical animal testing that is scheduled to begin in late April 2020.. The newly added 5th linear DNA vaccine candidate encodes an engineered fusion protein of a COVID-19 Spike domain with an immunomodulator moiety, indicated ...

The attenuated live M. bovis Bacille-Calmette-Guérin (BCG) is still the sole vaccine used against tuberculosis, but confers only variable efficacy against adult pulmonary tuberculosis (TB). Though no clear explanation for this limited efficacy has been given, different hypotheses have been advanced, such as the waning of memory T-cell responses, a reduced antigenic repertoire and the inability to induce effective CD8+ T-cell responses, which are known to be essential for latent tuberculosis control. In this study, a new BCG-based vaccination protocol was studied, in which BCG was formulated in combination with a plasmid DNA vaccine. As BCG is routinely administered to neonates, we have evaluated a more realistic approach of a simultaneous intradermal coadministration of BCG with pDNA encoding the prototype antigen, PPE44. Strongly increased T- and B-cell responses were observed with this protocol in C57BL/6 mice when compared to the administration of only BCG or in combination with an empty pDNA

Inovio Pharmaceuticals is developing VGX 3100, a SynCon® therapeutic DNA vaccine for the treatment of high-grade HPV-caused pre-cancers and other related

Inovio Pharmaceuticals, Inc. announced that it has achieved compelling immune responses in a study of its multi-subtype DNA vaccine for foot-and-mouth (FMD) disease administered by its proprietary vaccine delivery technology in sheep, the second large animal in which this vaccine was evaluated. Strong protective neutralizing antibodies were also observed in pigs vaccinated with the same vaccine.

In an effort to make affordable vaccines suitable for the regions most affected by HIV-1, we have constructed stable vaccines that express an HIV-1 subtype C mosaic Gag immunogen (BCG-GagM, MVA-GagM and DNA-GagM). Mosaic immunogens have been designed to address the tremendous diversity of this virus. Here we have shown that GagM buds from cells infected and transfected with MVA-GagM and DNA-GagM respectively and forms virus-like particles. Previously we showed that a BCG-GagM prime MVA-GagM boost generated strong cellular immune responses in mice. In this study immune responses to the DNA-GagM and MVA-GagM vaccines were evaluated in homologous and heterologous prime-boost vaccinations. The DNA homologous prime boost vaccination elicited predominantly CD8+ T cells while the homologous MVA vaccination induced predominantly CD4+ T cells. A heterologous DNA-GagM prime MVA-GagM boost induced strong, more balanced Gag CD8+ and CD4+ T cell responses and that were predominantly of an effector memory ...

With regard to schistosomiasis in humans, serious symptoms of schistosomiasis generally appear in people who harbor large numbers of parasites, and thus a vaccine able to effectively reduce a patients worm burden by 50% or more could dramatically reduce the number of severe cases of the disease, decreasing morbidity. Furthermore, as with vaccination of water buffalo, a 50% efficacious vaccine for human schistosomiasis would decrease transmission of the disease (18). In this study, two large experiments were carried out that compared multiple vaccination parameters. We found that vaccination with cocktail plasmid DNA vaccines that included a boost administered by electroporation increased vaccine efficacy by greater than 40%. Importantly, the addition of a protein cocktail vaccine boost to this effective regimen elevated efficacy to approximately 60% for adult worm burden reduction and greater than 60% for liver egg reduction. Employment of either vaccine regimen in water buffalo alone, combined ...

One of the major challenges for the development of an HIV vaccine is to induce potent virus-specific immune responses at the mucosal surfaces where transmission of virus occurs. Intranasal delivery of classical vaccines has been shown to induce good mucosal antibody responses, but so far for genetic vaccines the success has been limited. This study shows that young individuals are sensitive to nasal immunization with a genetic vaccine delivered in a formulation of a lipid adjuvant, the Eurocine N3. Intranasal delivery of a multiclade/multigene HIV-1 genetic vaccine gave rise to vaginal and rectal IgA responses as well as systemic humoral and cellular responses. As electroporation might become the preferred means of delivering genetic vaccines for systemic HIV immunity, nasal delivery by droplet formulation in a lipid adjuvant might become a means of priming or boosting the mucosal immunity. © 2008 Elsevier Ltd. All rights reserved.. ...

DNA vaccines or proteins are capable of inducing specific immunity; however, the translation to the clinic has generally been problematic, primarily due to the reduced magnitude of immune response and poor pharmacokinetics. Herein we demonstrate a composite microsphere formulation, composed of mesoporous silica spheres (MPS) and poly(d,l-lactide-co-glycolide) (PLGA), enables the controlled delivery of a prime-boost vaccine via the encapsulation of plasmid DNA (pDNA) and protein in different compartments. Method with modified dual-concentric-feeding needles attached to a 40 kHz ultrasonic atomizer was studied. These needles focus the flow of two different solutions, which passed through the ultrasonic atomizer. The process synthesis parameters, which are important to the scale-up of composite microspheres, were also studied. These parameters include polymer concentration, feed flowrate, and volumetric ratio of polymer and pDNA-PEI/MPS-BSA. This fabrication technique produced composite ...

ObjectiveTo develop a DNA cancer vaccine that targets the vascular endothelial growth factor receptor.DesignMice were vaccinated intramuscularly with listerioly

Interest in vaccine development has been rekindled over recent years due to the failure to treat infections caused by multiresistant bacteria. New technological developments such as immunoproteomics provide the platform for identifying appropriate immunogenic proteins for new vaccine design. Recombinant technology has enabled researchers to develop molecular vaccines which have been shown to elicit both cellular and humoral responses (7, 20).. We have shown that both OmpA and OmpK36 are strongly immunogenic (17), and in this investigation, the gene encoding each of the antigens was cloned in a eukaryotic plasmid which was administered as a DNA vaccine. Our results confirmed that recombinant pVAX1 plasmids containing either the ompA or the ompK36 gene were able to express the respective protein in the mammalian cells. OmpA and OmpK36 antibodies were detected in the sera of animals vaccinated with the pOmpA or the pOmpK36 plasmids.. The IgG subclass of antibodies produced against the DNA vaccine ...

Janssen Pharmaceuticals, Inc., part of the Janssen Pharmaceutical Companies of Johnson & Johnson, announced today that it has entered into a worldwide exclusive license and collaboration agreement with Bavarian Nordic to leverage their MVA-BN technology with Janssen s own AdVac and DNA-based vaccine technologies in the development and commercialization of potential new vaccine regimens against hepatitis B virus (HBV) and the human immunodeficiency virus (HIV-1). This agreement stems from...

Toxoplasma gondii is a widely prevalent intracellular parasite which infects almost all warm-blooded animals including humans and causes serious zoonotic toxoplasmosis. DNA vaccines have proved effective in the protection against parasites. However, the problems of weak immunity and inefficient delivery of DNA vaccine remain major issues. Therefore, comprehensive antigens derived from all stages of the parasite, effective adjuvants and delivery systems should be considered in the vaccine construction. SAG3101-144,ROP18347-396, MIC6288-347, GRA7182-224, MAG158-125, BAG1156-211 andSPA142-200, derived from antigens in tachyzoite, bradyzoite and sporozoite stages of T. gondii were screened based on CD8+ T cell epitope binding affinity to HLA and H-2. We constructed a recombinant DNA vaccine and an adenovirus vaccine encoding multi-stage antigen of T. gondii linked to ubiquitin molecules and vaccinated BALB/cmice with different strategies. Antibodies, cytokines, splenocytes

Vaccines have classically been used for disease prevention. Modern clinical vaccines are continuously being developed for both traditional use as well as for new applications. Typically thought of in terms of infectious disease control, vaccination approaches can alternatively be adapted as a cancer therapy. Vaccines targeting cancer antigens can be used to induce anti-tumour immunity and have demonstrated therapeutic efficacy both pre-clinically and clinically. Various approaches now exist and further establish the tremendous potential and adaptability of anti-cancer vaccination. Classical strategies include ex vivo-loaded immune cells, RNA- or DNA-based vaccines and tumour cell lysates. Recent oncolytic virus development has resulted in a surge of novel viruses engineered to induce powerful tumour-specific immune responses. In addition to their use as cancer vaccines, oncolytic viruses have the added benefit of being directly cytolytic to cancer cells and thus promote antigen recognition within a

Read Characterisation of IE and UL5 gene products of equine herpesvirus 1 using DNA inoculation of mice, Archives of Virology on DeepDyve, the largest online rental service for scholarly research with thousands of academic publications available at your fingertips.

Genetic vaccination using naked plasmid DNA is an immunization strategy both against infectious diseases and cancer. In order to improve the efficacy of DNA vaccines, particularly in large animals and humans, different strategies have been pursued. These vaccination strategies are based on different application routes, schedules, and coexpression of immunomodulatory molecules as adjuvants. Our mouse tumor model offers the possibility to investigate Her2/neu DNA vaccines in different settings, i.e., intramuscular or intradermal application with or without coexpression of adjuvants. Protection from tumor growth in tumor challenge experiments and both T cell and humoral immune responses against Her2/neu peptides are used as surrogate parameters for vaccine efficacy.. ...

...BLUE BELL Pa. March 14 2011 /- Inovio Pharmaceuticals...In a Phase I clinical trial of ChronVac-C using Inovios MedPulser ...This Phase II follow-on trial is an open-label single-dose randomize...,Inovio,Pharmaceuticals,Partner,ChronTech,Initiates,Phase,II,Clinical,Trial,of,Hepatitis,C,Virus,DNA,Vaccine,Using,Inovios,Electroporation,Delivery,Technology,medicine,advanced medical technology,medical laboratory technology,medical device technology,latest medical technology,Health

Our data demonstrate that a single dose of a DNA vaccine or a purified inactivated virus vaccine provides complete protection against the ZIKV challenge in mice, said senior author Dan H. Barouch, adding Importantly, we showed that vaccine-induced antibodies provided protection, similar to existing vaccines for other flaviviruses.. The researchers tested two vaccine candidates: a DNA vaccine developed in the Barouch laboratory at BIDMC, and a purified inactivated virus vaccine developed at WRAIR. The DNA vaccine used gene sequences from a ZIKV strain from Brazil to elicit immune responses.. Four weeks following vaccination, mice were exposed to the Brazilian strain of ZIKV, which had previously been shown to cause defects in fetal mice similar to those observed in ZIKV infected humans. All vaccinated mice were protected from ZIKV replication. Other mice were vaccinated and exposed to infection eight weeks later and were also protected from infection.. Barouch noted that the effectiveness of ...

This press release contains forward-looking statements subject to risks and uncertainties that could cause actual results to differ materially from those projected, including: whether Vical or others will continue development of the Ebola vaccine; whether Vical or others will evaluate potential additional applications of the companys technology; whether the Ebola vaccine or any other product candidates will be shown to be safe and effective; whether the companys processes will result in rapid development and manufacturing of vaccines; the timing, nature and cost of clinical trials; whether Vical or its collaborative partners will seek or gain approval to market any product candidates; whether the Animal Rule will be applicable to DNA-based products and whether it will provide a favorable regulatory pathway; whether Vical or its collaborative partners will succeed in marketing any product candidates; whether any funding under Project BioShield will be directed to the Ebola DNA vaccine; and ...

The DNA vaccine in this report refers to the vaccines manufactured using recombinant DNA technology. The advent of these vaccines has revolutionized the he

Wijesundara, D & RANASINGHE, C 2012, Prime boost regimens for enhancing immunity: magnitude, quality of mucosal and systemic gene vaccines, in J Thalhamer, R Weiss, S Scheiblhofer (ed.), Gene Vaccines, Landes Bioscience/Springer Science+Business Media, New York, pp. 183-204. ...

臺大位居世界頂尖大學之列，為永久珍藏及向國際展現本校豐碩的研究成果及學術能量，圖書館整合機構典藏（NTUR）與學術庫（AH）不同功能平台，成為臺大學術典藏NTU scholars。期能整合研究能量、促進交流合作、保存學術產出、推廣研究成果。. To permanently archive and promote researcher profiles and scholarly works, Library integrates the services of NTU Repository with Academic Hub to form NTU Scholars.. ...

Diane Griffin, M.D., Ph.D., of Johns Hopkins University Bloomberg School of Public Health will be presenting findings on Thursday, May 31 at the 10th Annual American Society of Gene Therapy meeting in Seattle showing that an experimental measles DNA vaccine showed promising results in infant monkeys and achieved

Thermostable Vaccine Formulations: to make vaccine deployment free of the cold-chain Three types of adjuvant are being investigated: Signalling, Structural and Cellular Trafficking.. Why not download the full presentation and discover more about new generation vectored vaccines - Pushing innovation beyond the antigen to meet the health needs of resource-poor settings. · Genetic adjuvants: (i) pro-inflammatory activators (ii) multimerisation of the antigen (iii) modulators of antigen processing · Thermostable formulations for vaccines · How to translate clinical efficacy to field effectiveness Download the full presentation here ,. For more information about this and other topics discussed at the World Vaccine Congress Lyon, subscribe to the Vaccine Nation newsletter, or visit the event website. For more updates on the vaccines industry, follow us on Twitter: @vaccinenation or join our LinkedIn group: Vaccine Nation. ...

For licensing purposes, besides the immunogenic aspects, deoxyribonucleic acid (DNA) vaccines present safety considerations that must be critically assessed during preclinical or/and clinical safety studies. The major concerns with regard to safety are integration of the plasmid DNA into the host ge …

Jon Rappoport, No More Fake News As my readers know, Ive been reporting on new types of technology that could be used in a coming COVID-19 vaccine-and warning about the consequences. One such technology is: DNA vaccines. They would alter recipients genetic makeup permanently. https://www.youtube.com/watch?v=-R8xlr7pjgI But Reuters has seen fit to claim:

Taking a two-month-old in for vaccination shots and watching them get stuck with six needles in rapid succession can be painful for child and parent alike. If the work of an MIT team of researchers pans out, those needles may be thing of the past thanks to a new dissolvable polymer film that allows ...

Immunization with DNA-based allergen vaccines has yielded promising results as a potentially novel modality of immunotherapy. Limitations to this approach include reduced immunologic responses in humans and relatively high concentrations of DNA vaccine required to induce immunity. Investigators examined the effectiveness of using a self-replicating (replicon) DNA vaccine to induce protection against allergenic sensitization in a mouse model. Mice were immunized intradermally with replicon Phl p5 DNA or conventional DNA vaccines followed by sensitization and intranasal challenge with Phl p5. Titers of IgG1, IgG2a and IgE were measured from sera, while eosinophil counts and cytokine levels were measured from BAL fluid. Lung sections were analyzed for presence of inflammatory infiltrates, increased mucus production and epithelial damage. Replicon DNA vaccination with Phl p5 resulted in reduced expression of specific IgE, Th1-biased cytokine expression, fewer eosinophils and reduced markers of ...

Dr. Gerald Zons latest Zone in with Zon blog post, dated December 2, 2013, and published by TriLink BioTechnologies of San Diego, provides a fascinating discussion of the developing use of modified mRNAs in a wide variety of key applications, including gene therapy, nucleic acid vaccines, and cellular reprogramming, as well as the possibly tremendous commercial potential of modified mRNA technology in these and other areas. Dr. Zon begins by discussing the intellectual simplicity of gene therapy, i.e., to simply replace a broken gene with the DNA of the normal gene and thus ultimately generate the normal version of the missing or altered protein. Unfortunately, it has proven remarkably difficult over three decades of work to achieve this effectively and safely. Dr. Zon attributes this in part to the challenges for cell- or tissue-specific delivery, as well as concern for adverse events generally ascribed to unintended vector integration leading to neoplasias. Nevertheless, there are presently ...

Both humoral and cellular immune responses are critical for the control of HIV infection and replication. We have established systems for production of HIV and SIV virus-like particles containing high levels of viral Env proteins using the baculovirus expression system. Evaluation of immunogenicity showed that immunization with virus-like particles induced both cellular and neutralizing antibody responses. Furthermore, mucosal administration of virus-like particles effectively induced both mucosal and systemic immune responses. These results indicate that virus-like particles consisting of HIV structural proteins are an attractive vaccine platform for eliciting anti-viral immune responses, especially neutralizing antibody responses. We have also synthesized codon-optimized genes for HIV Env proteins and evaluated their immunogenicity. Combinations of virus-like particle and DNA-based vaccination are promising for inducing strong cellular and neutralizing antibody responses against HIV ...

RANASINGHE, C & Ramshaw, I 2009, Genetic heterologous prime-boost vaccination strategies for improved systemic and mucosal immunity, Expert Review of Vaccines, vol. 8, no. 9, pp. 1171-1181. ...

(CIDRAP News) Federal officials have announced the launch of the first clinical trial of an H5N1 avian influenza vaccine made from a piece of the viruss DNA rather than from the whole virus, an approach that may facilitate faster vaccine production.

Vaccine TechnologiesMedigen is a pioneer of novel vaccine technologies that provide inherent biological safety and unsurpassed efficacy to our vaccines. Medigens platform vaccine technologies are represented by engineered live vaccines, recombinant virus

Our Patented DNA ministrings are the safest and most efficacious DNA vectors for nonviral gene delivery. Their topology as linear covalently closed (stable) strings makes them the safest tools for therapeutic DNA delivery or genomic manipulation to date.. We designed the production platform this way from inception, and we have tested and published these outcomes in Nature affiliate journals. DNA ministrings are made through a simple shift in temperature in bacteria which makes them scalable and inexpensive to produce versus competitors that fall dramatically short in terms of production efficiency. Our current application targets colorectal (CRC) as proof of principle. Future targets include prostate cancer, intractable disease and monogenic disorders such as cystic fibrosis ...

When we have outbreaks like Ebola or Zika, there are scientists in research labs working day in and day out to find answers, treatments, or vaccines to protect us. Now, a Hattiesburg High School gr...

I have chosen this subject because I have been involved in researching how RNA vaccinations can work to fight cancer since joining TRON in 2011, and more recently in combination with Antibody therapy, focussing mainly on checkpoint inhibitors (CPI) and local radio therapy.. It is indeed a very important topic because RNA vaccination is the most adaptable platform developed thanks to the molecular biology techniques raised in the well-known field of synthetic medicine or genetic vaccines. Just how important RNA vaccines are in infectious diseases emerged globally very recently. However, what scientists perhaps would not know is that this specific therapeutic platform was initiated more than 10 years ago to cure cancer patients and for the medical need of protein replacement therapies. This is a field that TRON in collaboration with BioNTech continues to work with the perspective of several types of combination therapies. The combination with local radiotherapy was planned in collaboration with ...

SAN DIEGO, Oct. 3, 2013-- Vical Incorporated today announced the publication of a new article 1 in a special DNA vaccine issue of the journal Vaccines detailing the development process from initial product concept to Phase 3 trial initiation for ASP0113, Vicals investigational therapeutic vaccine designed to control cytomegalovirus in transplant recipients.

Ive been at this blogging thing for well over 12 years now. I know, I know. Sometimes it amazes even me that I been doing this so long. I also know that Ive been mentioning just how long Ive been blogging more frequently. Sometimes I worry that the blog will turn into nothing more than posts counting down the days since I started this whole crazy thing. Of course, the main reason I mention this is not so much out of a desire for repetition but as a way of expressing amazement when I find something new and/for bizarre that I dont recall having heard before. So it was when I came across an ...

A parent who wished to make an informed decision on vaccinating their child and the difficulty they incurred at not being told the complete story.

Gorbunova and her team were able to make their observations by working with genetically-modified mice whose cells produce green fluorescent protein (GFP) that glows each time the breaks are repaired. By tracking how many cells glowed green in different tissues, the researchers determined the efficiency of repair.. We showed two things with these genetically-modified mice, said Gorbunova. Not only did the efficiency of DNA repair decline with age, but the mice began using a sloppier repair mechanism, leading to more mutations, particularly in the heart and lungs.. DNA breaks occur frequently because animal cells are under constant assault from routine activities in the environment-whether by a blast of X-rays from a visit to the doctor or simply breathing in oxygen-and, as a result, the DNA molecules often get damaged.. Using the genetically modified mice, the research team can now look at how diet, medicines, and different genetic factors also affect DNA repair in mice.. These mice may very ...

Creative Biolabs provides Mouse Anti-MS4A1 DNA-encoded mAb (Clone CBXC-2630), pVAX1 product for Biopharmaceutical research,preclinical and clinical trials.